Conditions: Neoplasms
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 20
Healthy volunteers: no

Brief summary:
This is a Phase II open-label exploratory trial of BIBW 2992 administered to patients with tumors of various histologies found to possess EGFR and/or HER2 gene amplification, or EGFR activating mutations.

Detailed description:

Arms:
arm 1: BIBW 2992 (Afatinib) for patients FISH positive for/or harboring EGFR or HER2 Mutation

Interventions: intervention 1: BIBW 2992 (Afatinib)
Intervention descriptions: intervention 1: BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation

Protocol document: